E-Z-Em develops virtual colonoscopy agent
E-Z-Em of Westbury, NY, announced this month that it has signedan agreement with Bowman Gray School of Medicine in Winston-Salem,NC, to develop an oral contrast agent for virtual colonoscopyprocedures under investigation at the hospital. The agent
E-Z-Em of Westbury, NY, announced this month that it has signedan agreement with Bowman Gray School of Medicine in Winston-Salem,NC, to develop an oral contrast agent for virtual colonoscopyprocedures under investigation at the hospital. The agent willminimize artifacts in 3-D images of the colon that can obscureor mimic polyps in virtual colonoscopy simulations. Virtual colonoscopyis being developed as an alternative to video-based colonoscopyscreening (SCAN 7/19/95).
In other news, E-Z-Em has introduced a new remote-controlledCT contrast injection system, PercuPump II. E-Z-Em used feedbackfrom radiologists and technologists in designing the system, whichuses a touch-screen remote control and features an optional thermalprinter to print a record of each patient's procedure.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
